Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07492680 · ClinicalTrials.gov registry record · Phase 2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT07492680 is a Phase 2 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 260 participants.
The verdict
NCT07492680, a Phase 2 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.
Interventions
- DRUG Temozolomide
- DRUG Pumitamig
- DRUG Daraxonrasib
- DRUG BMS-986504
- DRUG Nivolumab + Relatlimab FDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2026-07-17 |
| Est. Completion | 2032-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07492680
The ClinicalTrials.gov registry entry for NCT07492680 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Temozolomide is the first listed.
NCT07492680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07492680 about?
NCT07492680 is a clinical study titled "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)". This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial wi...
What is the current status of trial NCT07492680?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2026-07-17. Estimated completion is 2032-05-20.
What interventions are being tested in trial NCT07492680?
The interventions under investigation include: Temozolomide (DRUG), Pumitamig (DRUG), Daraxonrasib (DRUG), BMS-986504 (DRUG), Nivolumab + Relatlimab FDC (DRUG).
Who is sponsoring clinical trial NCT07492680?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.